Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

The First Affiliated Hospital of Soochow University is the lead sponsor of 117 current clinical trials in our China register. 82 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Venetoclax, Azacitidine and Chidamide. The most-studied condition is Acute Myeloid Leukemia.

ClinicalTrials.gov trials by status

Recruiting8270%
Not yet open1916%
Active, closed119%
By invitation54%

Trials by phase

Phase 23933%
Not applicable2421%
Observational1916%
Phase 198%
Phase 1/287%
Phase 2/376%
Phase 343%
Phase EARLY_PHASE143%
Phase 433%

Clinical trials sponsored by The First Affiliated Hospital of Soochow University

117 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML NCT06879847 · Relapsed or Refractory Acute Myeloid Leukemia	Not applicable	Recruiting	2024-12	China
A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia NCT07028073 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia With T(8;21)(Q22;Q22), Acute Myeloid Leukemia With T(16;16)(P13;Q22), KIT Gene Mutation	Phase 1/2	Recruiting	2025-05	China
AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging NCT07551466 · ClinicalTrials.gov ↗ · Early Gastric Cancer	Observational	Recruiting	2026-05	China
Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma NCT03196414 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1/2	Recruiting	2016-09	China
Construction of a Database for TTP NCT05571774 · ClinicalTrials.gov ↗ · TTP - Thrombotic Thrombocytopenic Purpura	Observational	Recruiting	2022-10	China
Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients NCT07400328 · ClinicalTrials.gov ↗ · Oral Mucositis, Stomatitis, Gastrointestinal Mucositis Drug: Amimestrocel	Phase 2	Recruiting	2026-02	China
U69-CART-Cells For R/R T-ALL NCT07350863 · ClinicalTrials.gov ↗ · Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma	Phase 1	Recruiting	2026-10	China
Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL NCT06393985 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia	Phase 2	Recruiting	2024-04	China
RN1201 Injection in the Treatment of Antibody-Mediated Diseases NCT07072247 · ClinicalTrials.gov ↗ · Refractory Immune-mediated Platelet Transfusion Refractoriness, Relapsed or Refractory Immune Thrombocytopenia	Phase 1	Recruiting	2025-07	China
Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL NCT06682130 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma(DLBCL)	Phase 2	Recruiting	2024-11	China
Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA NCT07400341 · ClinicalTrials.gov ↗ · MDS (Myelodysplastic Syndrome), Aplastic Anemia (AA) Drugs: Recombinant human thrombopoietin, RhTPO, Romiplostim	Phase 2	Recruiting	2026-01	China
Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients NCT06682156 · ClinicalTrials.gov ↗ · Newly Diagnosed Multiple Myeloma Drug: Carfilzomib	Observational	Recruiting	2024-09	China
Repeated Transcranial Magnetic Stimulation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial NCT07581756 · ClinicalTrials.gov ↗ · Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea (IBS-D), Repetitive Transcranial Magnetic Stimulation (rTMS)	Not applicable	Recruiting	2024-12	China
Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) NCT06960369 · ClinicalTrials.gov ↗ · Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea (IBS-D), Repetitive Transcranial Magnetic Stimulation (rTMS)	Phase 1	Recruiting	2024-12	China
VABu Conditioning in Elderly AML HSCT NCT07583888 · ClinicalTrials.gov ↗ · Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Acute Myeloid Leukemia (AML)	Phase 2/3	Recruiting	2026-05	China
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. NCT07372365 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma (MZL)	Phase 2	Recruiting	2025-10	China
Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosis NCT07670130 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)	Observational	Recruiting	2026-06	China
Romiplostim for Oral TPO-RA Resistant ITP NCT07612319 · ClinicalTrials.gov ↗ · Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Drug: Romiplostim	Not applicable	Recruiting	2026-03	China
Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients NCT07074457 · ClinicalTrials.gov ↗ · CD30+ Peripheral T-cell Lymphoma	Not applicable	Recruiting	2024-11	China
Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia NCT07206823 · ClinicalTrials.gov ↗ · Primacy Immune Thrombocytopenia	Not applicable	Recruiting	2025-09	China
BY002 IIT Study in R/R Acute Leukemia NCT07270770 · ClinicalTrials.gov ↗ · Acute Leukemia, KMT2A Rearrangements or NPM1 Mutations Acute Leukemia Drug: BY002	Phase 1	Recruiting	2026-03	China
Peripheral Blood KIT-D816V Mutation in Adult Systemic Mastocytosis NCT07562542 · ClinicalTrials.gov ↗ · Systemic Mastocytosis, KIT-D816V Mutation	Observational	Recruiting	2025-05	China
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients NCT07159620 · ClinicalTrials.gov ↗ · Adult T-cell Leukemia/Lymphoma Drugs: Azacitidine, Chidamide, Dexamethasone	Phase 2	Recruiting	2025-09	China
Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients NCT04025450 · ClinicalTrials.gov ↗ · Multiple Myeloma Drug: Chidamide	Phase 1/2	Recruiting	2019-07	China
Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL NCT07072208 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma	Not applicable	Recruiting	2024-11	China
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis NCT07015762 · ClinicalTrials.gov ↗ · Atopic Dermatitis Drug: IBI3002	Phase 1	Recruiting	2025-07	China
Dapagliflozin in Allo-HCT for aGVHD NCT06626737 · ClinicalTrials.gov ↗ · Graft-versus-host Disease (GVHD) Drug: Dapagliflozin	Phase 2	Recruiting	2025-04	China
A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia NCT07499284 · ClinicalTrials.gov ↗ · Aplastic Anaemia	Not applicable	Recruiting	2025-10	China
Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer NCT07647263 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer Drugs: Pertuzumab, Trastuzumab, Trastuzumab Rezetecan	Phase 2	Recruiting	2026-03	China
A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients NCT07500753 · ClinicalTrials.gov ↗ · Relapsed or Refractory Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome)	Not applicable	Recruiting	2026-04	China
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia NCT06730256 · ClinicalTrials.gov ↗ · Relapsed/Refractory Plasma Cell Leukemia, Relapsed/Refractory Multiple Myeloma	Phase EARLY_PHASE1	Recruiting	2025-07	China
VA vs DA for Newly Diagnosed Hig-risk AML NCT05939180 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Drugs: Daunorubicin, Venetoclax	Phase 2/3	Recruiting	2024-04	China
CAV Regimen for R/R AML NCT05657639 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	2022-10	China
Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia NCT06532552 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Adult, Newly Diagnosed	Phase 2	Recruiting	2024-07	China
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia NCT06696833 · ClinicalTrials.gov ↗ · B-Cell Acute Lymphoblastic Leukemia, Adult Drugs: Cyclophosphamide, Fludarabine	Phase EARLY_PHASE1	Recruiting	2024-12	China
VAC Regimen for AML Patients Who Failed to Response to VA Regimen NCT06220162 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Drugs: Chidamide, Venetoclax and azacitidine	Phase 2	Recruiting	2024-02	China
A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT NCT07559695 · ClinicalTrials.gov ↗ · Menin Inhibitors, Acute Leukemia, Post Hematopoietic Stem Cell Transplantation	Observational	Recruiting	2025-11	China
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib NCT07463651 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), FLT3-ITD Mutation, Allogeneic Hematopoietic Cell Transplantation (HCT) Drugs: Gilteritinib, Sorafenib	Phase 3	Recruiting	2026-05	China
Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients NCT06394011 · ClinicalTrials.gov ↗ · Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia	Phase 2	Recruiting	2024-02	China
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection NCT06409702 · ClinicalTrials.gov ↗ · Newly Diagnosed, High Risk, MRD Drugs: Carfilzomib, Daratumumab, Dexamethasone	Phase 4	Recruiting	2024-06	China
Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL NCT07372352 · ClinicalTrials.gov ↗ · Peripheral T Cells Lymphoma (PTCL)	Phase 2	Recruiting	2026-01	China
Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma NCT07652138 · ClinicalTrials.gov ↗ · Multiple Myloma, Newly Diagnosed Multiple Myeloma (NDMM) Drug: BCMA/CD19-targeted allogeneic CAR-T	Phase 1	Recruiting	2025-07	China
FMT in Gut aGVHD Treated NCT03148743 · ClinicalTrials.gov ↗ · Acute-graft-versus-host Disease Drug: Fecal Microbiota	Observational	Recruiting	2017-05	China
The Enhancement of Diagnostic and Grading Efficacy of Prostate Cancer by New MRI Sequences: A Prospective Observational Study Based on New MRI Sequences in a Single Center NCT07552285 · ClinicalTrials.gov ↗ · Prostate Cancer, Prostate Cancer (Diagnosis)	Observational	Recruiting	2025-05	China
CMV-CMI in csCMVi After HSCT NCT07688759 · ClinicalTrials.gov ↗ · Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT), Immune Reconstitution	Observational	Recruiting	2026-06	China
Effect of VR-MBCT in Chronic Nonspecific Low Back Pain NCT07589790 · ClinicalTrials.gov ↗ · Chronic Non-specific Low Back Pain	Not applicable	Recruiting	2026-04	China
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT NCT05772273 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Drugs: Azacitidine, Camrelizumab	Not applicable	Recruiting	2023-03	China
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation NCT07499271 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL) Drugs: Orelabrutinib, Pola-R-Chp	Phase 2	Recruiting	2026-01	China
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma NCT05182957 · ClinicalTrials.gov ↗ · Relapsed/Refractory Peripheral T-cell Lymphoma	Phase 2	Recruiting	2020-01	China
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy NCT06985485 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab	Phase 2	Recruiting	2025-05	China
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia NCT05566054 · ClinicalTrials.gov ↗ · Acute Monocytic Leukemia, Newly Diagnosed Drugs: Azacitidine, Chidamide, Venetoclax	Phase 2	Recruiting	2022-03	China
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission NCT05404906 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML) in Remission Drugs: Azacitidine, Venetoclax	Phase 2/3	Recruiting	2022-06	China
Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia NCT07101497 · ClinicalTrials.gov ↗ · Menin Inhibitors, Post Hematopoietic Stem Cell Transplantation, Maintenance Therapy Drug: BN104	Phase 2	Recruiting	2025-08	China
Lf-rTMS Attenuates Visceral Pain in Irritable Bowel Syndrome With Diarrhea NCT06757491 · ClinicalTrials.gov ↗ · Repetitive Transcranial Magnetic Stimulation, Chronic Visceral Pain, Functional Magnetic Resonance Imaging	Not applicable	Recruiting	2024-08	China
Efficacy and Safety of Auto-FMT in Preventing aGVHD NCT04745221 · ClinicalTrials.gov ↗ · Graft Versus Host Disease, Acute	Not applicable	Recruiting	2021-03	China
Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients NCT06381817 · ClinicalTrials.gov ↗ · Acute T Cell Lymphoblastic Leukemia, Haploidentical Hematopoietic Stem Cell Transplantation, Cord Blood	Phase 3	Recruiting	2024-04	China
Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML NCT07451912 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML Drug: Venetoclax	Phase 1/2	Recruiting	2025-09	China
Relationship Between "FODMAPs" and "GVHD" NCT04660487 · ClinicalTrials.gov ↗ · Graft Versus Host Disease	Observational	Recruiting	2020-12	China
CAV Regimen for R/R Ph- B-ALL NCT05657652 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia	Not applicable	Recruiting	2022-10	China
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL NCT07255963 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma	Phase 2	Recruiting	2025-11	China
Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. NCT07074496 · ClinicalTrials.gov ↗ · Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Drugs: Cyclophosphamide, Fludarabine, Olverembatinib	Phase EARLY_PHASE1	Recruiting	2024-01	China
Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT NCT06812598 · ClinicalTrials.gov ↗ · Cytomegalovirus Infections, CMV	Not applicable	Recruiting	2024-12	China
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Asthma NCT07015749 · ClinicalTrials.gov ↗ · Asthma Drug: IBI3002	Phase 1	Recruiting	2025-06	China
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML NCT05805098 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2/3	Recruiting	2023-03	China
Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia NCT06816134 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell	Phase 2	Recruiting	2025-01	China
TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT NCT06125483 · ClinicalTrials.gov ↗ · Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation	Not applicable	Recruiting	2023-11	China
Olverembatinib for FGFR1-rearranged Neoplasms NCT05521204 · ClinicalTrials.gov ↗ · Myeloproliferative Neoplasm, Acute Leukemia Drug: Olverembatinib	Phase 2	Recruiting	2022-09	China
CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma NCT06486337 · ClinicalTrials.gov ↗ · NHL	Phase 2	Recruiting	2024-07	China
Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL NCT06507514 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia	Phase 1	Recruiting	2024-04	China
Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients NCT07072221 · ClinicalTrials.gov ↗ · Peripheral T-cell Lymphoma	Not applicable	Recruiting	2024-11	China
The Impact of Local Anesthetic Solution Temperature on Epidural-related Maternal Fever NCT06682416 · ClinicalTrials.gov ↗ · Epidural Related Maternal Fever, Analgesia, Epidural, Fever	Not applicable	Recruiting	2024-11	China
A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic Diseases NCT06548958 · ClinicalTrials.gov ↗ · Malignant Hematological Diseases	Not applicable	Recruiting	2024-07	China
Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL NCT07074470 · ClinicalTrials.gov ↗ · Primary Central Nervous System Lymphoma (PCNSL)	Not applicable	Recruiting	2025-01	China
Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL NCT07059741 · ClinicalTrials.gov ↗ · Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)	Not applicable	Recruiting	2024-12	China
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma NCT07270835 · ClinicalTrials.gov ↗ · Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma Drugs: Rituximab, Zanubrutinib	Phase 4	Recruiting	2025-11	China
Nutritional Status of Patients After Hematopoietic Stem Cell Transplantation NCT04146870 · ClinicalTrials.gov ↗ · Nutrition, Hematopoietic Stem Cell Transplantation	Observational	Recruiting	2018-10	China
Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia NCT07564453 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Drug: Blinatumomab	Phase 2	Recruiting	2025-04	China
Venetoclax Combined With Azacitidine for Consolidation Therapy in AML NCT07425782 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Consolidation Therapy, Venentoclax	Phase 2	Recruiting	2026-02	China
a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia NCT07007949 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, IDH1 Gene Mutation, Ivosidenib Drugs: Ivosidenib, Venetoclax and azacitidine	Phase 2	Recruiting	2025-06	China
Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients NCT05376111 · ClinicalTrials.gov ↗ · T-cell Acute Lymphoblastic Leukemia, Recruiting Drug: Venetoclax/Azacitidine	Phase 2	Recruiting	2022-04	China
VA Consolidation in Intermediate-Risk AML NCT07672262 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Intermediate Risk Acute Myeloid Leukemia, Consolidation Therapy Drug: Venetoclax and azacitidine	Phase 2	Recruiting	2026-06	China
Construction of a Database for TMA NCT05634928 · ClinicalTrials.gov ↗ · Thrombotic Microangiopathies	Observational	Recruiting	2022-12	China
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML NCT07486479 · Acute Myeloid Leukemia (AML) Drugs: Azacitidine, Cytarabine, Idarubicin	Phase 3	Not yet open	2026-03	China
A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia NCT07573670 · ClinicalTrials.gov ↗ · Newly Diagnosed Mixed Phenotype Acute Leukemia Drugs: Azacitidine, Blinatumomab	Phase 2	Not yet open	2026-05	China
A Study of VABu Conditioning Regimen in Allo-HSCT for AML Patients NCT07762508 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute(AML), Hematopoietic Stem Cell Transplantation (HSCT) Drugs: Antithymocyte globulin, Ara-C, Azacitidine	Not applicable	Not yet open	2026-08	China
A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL NCT05931757 · ClinicalTrials.gov ↗ · Philadelphia-Positive ALL Drug: Olverembatinib	Phase 2	Not yet open	2023-07	China
SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS NCT07575412 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS	Phase 2	Not yet open	2026-06	China
U96-CAR-T-Cells For R/R B-ALL NCT07511426 · ClinicalTrials.gov ↗ · Relapsed or Refractory B Cell Leukemia and Lymphoma	Phase 1	Not yet open	2026-07	China
Younger vs. Older Donors in Allo-HSCT: TTE NCT07666568 · ClinicalTrials.gov ↗ · A Target Trial Emulation Study, Donor Age, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Observational	Not yet open	2026-07	China
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS NCT07562568 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS	Phase 2	Not yet open	2026-06	China
Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia NCT06559644 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute, B-cell Acute Lymphoblastic Leukemia	Phase EARLY_PHASE1	Not yet open	2024-09	China
Safety and Feasibility of FMT for Immune Recovery After HSCT NCT07755319 · ClinicalTrials.gov ↗ · Humoral Immunodeficiency, Hematopoietic Stem Cell Transplantation Drug: Fecal Microbiota Transplantation	Phase 1/2	Not yet open	2026-08	China
Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma NCT07774234 · ClinicalTrials.gov ↗ · Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma Drugs: Gemcitabine, Glofitamab, Obinutuzumab	Phase 2	Not yet open	2026-08	China
Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis NCT06951971 · ClinicalTrials.gov ↗ · Hemophagocytic Lymphohistiocytosis (HLH)	Phase 2/3	Not yet open	2025-06	China
A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen NCT07709884 · ClinicalTrials.gov ↗ · Newly Diagnosed Multiple Myeloma, T(11;14), Sotoclax Drugs: Carfilzomib, Dexamethasone, Lenalidomide	Phase 4	Not yet open	2026-07	China
Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia NCT06841952 · ClinicalTrials.gov ↗ · AML, Adult Drugs: ATRA, Azacitidine, Venetoclax	Not applicable	Not yet open	2025-02	China
Cousin vs. Sibling Donors in Haplo-HSCT NCT07662382 · ClinicalTrials.gov ↗ · Hematopoietic Malignancies, Haploidentical Hematopoietic Stem Cell Transplantation, Donor	Observational	Not yet open	2026-08	China
BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients NCT06673459 · ClinicalTrials.gov ↗ · T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Total Body Irradiation	Phase 3	Not yet open	2024-12	China
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma NCT07609446 · ClinicalTrials.gov ↗ · Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma	Observational	Not yet open	2026-05	China
A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT07599423 · ClinicalTrials.gov ↗ · Diffuse Large B Cell Lymphoma (DLBCL)	Phase 2	Not yet open	2026-07	China

Showing the 100 most recently updated of 117 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in The First Affiliated Hospital of Soochow University trials

56 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 16 more in the trial list above.

Conditions in The First Affiliated Hospital of Soochow University trials

158 conditions

Acute Myeloid Leukemia14 Acute Myeloid Leukemia (AML)5 Acute Lymphoblastic Leukemia5 Multiple Myeloma4 Hematopoietic Stem Cell Transplantation4 B-cell Acute Lymphoblastic Leukemia4 Acute Leukemia4Transplantation, Stem Cell3Newly Diagnosed3Maintenance Therapy3Hematopoietic Stem Cell Transplantation (HSCT)2MDS2MDS (Myelodysplastic Syndrome)2Newly Diagnosed Multiple Myeloma2Irritable Bowel Syndrome2Irritable Bowel Syndrome With Diarrhea (IBS-D)2Repetitive Transcranial Magnetic Stimulation (rTMS)2ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION2Menin Inhibitors2Post Hematopoietic Stem Cell Transplantation2Intermediate Risk Acute Myeloid Leukemia2High Risk2Cytomegalovirus Infections2Haploidentical Hematopoietic Stem Cell Transplantation2

By trial register

Register	Trials	Recruiting
Clinical trials in China	117	82

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Acute Myeloid Leukemia

Sponsor	Trials
First Affiliated Hospital of Zhejiang University	6
Taiho Oncology	5
Peking University People's Hospital	5
Zhejiang University	5
Shenzhen Geno-Immune Medical Institute	4
Stichting Hemato-Oncologie voor Volwassenen Nederland	3
Orca Biosystems	3
Shanghai Jiao Tong University School of Medicine	3
Kura Oncology	2
Shenzhen University General Hospital	2

Sponsors with the most current trials registered for this condition.

Questions about The First Affiliated Hospital of Soochow University trials

How many clinical trials does The First Affiliated Hospital of Soochow University sponsor?

The First Affiliated Hospital of Soochow University is the lead sponsor of 117 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are The First Affiliated Hospital of Soochow University trials recruiting?

Yes. 82 of its 117 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is The First Affiliated Hospital of Soochow University testing?

Its current trials name 56 drugs and biologicals as interventions. The most frequent are Venetoclax (10), Azacitidine (9), Chidamide (4), Carfilzomib (3) and Cyclophosphamide (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

The First Affiliated Hospital of Soochow University clinical trials